In Brief: Myeloid‐derived suppressor cells in cancer

The role of myeloid‐derived suppressor cells (MDSCs) in cancer development has become clear over recent years, and MDSC targeting is an emerging opportunity for enhancing the effectiveness of current anticancer therapies. As MDSCs are not only able to limit anti‐tumour T‐cell responses, but also to...

Descripción completa

Detalles Bibliográficos
Autores principales: Solito, S, Pinton, L, Mandruzzato, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2017
Materias:
In Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413806/
https://www.ncbi.nlm.nih.gov/pubmed/28097660
http://dx.doi.org/10.1002/path.4876
_version_ 1783233235848790016
author Solito, S
Pinton, L
Mandruzzato, S
author_facet Solito, S
Pinton, L
Mandruzzato, S
author_sort Solito, S
collection PubMed
description The role of myeloid‐derived suppressor cells (MDSCs) in cancer development has become clear over recent years, and MDSC targeting is an emerging opportunity for enhancing the effectiveness of current anticancer therapies. As MDSCs are not only able to limit anti‐tumour T‐cell responses, but also to promote tumour angiogenesis and invasion, their monitoring has prognostic and predictive value. Herein, we review the key features of MDSCs in cancer promotion. © 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
format Online
Article
Text
id pubmed-5413806
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-54138062017-05-15 In Brief: Myeloid‐derived suppressor cells in cancer Solito, S Pinton, L Mandruzzato, S J Pathol In Brief The role of myeloid‐derived suppressor cells (MDSCs) in cancer development has become clear over recent years, and MDSC targeting is an emerging opportunity for enhancing the effectiveness of current anticancer therapies. As MDSCs are not only able to limit anti‐tumour T‐cell responses, but also to promote tumour angiogenesis and invasion, their monitoring has prognostic and predictive value. Herein, we review the key features of MDSCs in cancer promotion. © 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. John Wiley & Sons, Ltd 2017-03-21 2017-05 /pmc/articles/PMC5413806/ /pubmed/28097660 http://dx.doi.org/10.1002/path.4876 Text en © 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle In Brief
Solito, S
Pinton, L
Mandruzzato, S
In Brief: Myeloid‐derived suppressor cells in cancer
title In Brief: Myeloid‐derived suppressor cells in cancer
title_full In Brief: Myeloid‐derived suppressor cells in cancer
title_fullStr In Brief: Myeloid‐derived suppressor cells in cancer
title_full_unstemmed In Brief: Myeloid‐derived suppressor cells in cancer
title_short In Brief: Myeloid‐derived suppressor cells in cancer
title_sort in brief: myeloid‐derived suppressor cells in cancer
topic In Brief
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413806/
https://www.ncbi.nlm.nih.gov/pubmed/28097660
http://dx.doi.org/10.1002/path.4876
work_keys_str_mv AT solitos inbriefmyeloidderivedsuppressorcellsincancer
AT pintonl inbriefmyeloidderivedsuppressorcellsincancer
AT mandruzzatos inbriefmyeloidderivedsuppressorcellsincancer

Ejemplares similares